Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

ombinations

On April 19, 2007 Shire completed its acquisition of New River by way of a short-form merger, in an all-cash transaction. The acquisition was effected by merging Shuttle Corporation, an indirect wholly owned subsidiary of Shire, with and into New River, with New River continuing as the surviving corporation. As consideration, Shire paid to New River's shareholders US$64 in cash for each share of New River common stock outstanding at the time of the acquisition.

The acquisition of New River allows Shire to capture the full economic value of VYVANSE, and gain control of the future development and commercialisation of this product.

VYVANSE for ADHD in paediatric patients was approved by the FDA on February 23, 2007 and Shire received notification from the DEA of the final Schedule II classification for VYVANSE on May 3, 2007.

The acquisition of New River has been accounted for as a purchase business combination in accordance with IFRS 3. Under the purchase method of accounting, the assets and liabilities of New River are recorded at their fair values at the acquisition date. The financial statements of Shire issued after the completion of the acquisition reflect these fair values, with the results of New River being included within the Consolidated Income Statement from April 19, 2007.

Total consideration, including amounts payable in respect of stock options, share appreciation rights ("SARs"), warrants over New River's common stock and costs directly attributable to the business combination was approximately US$2.6 billion at the price of US$64 per share of New River's common stock, as analysed below:

US$M

__________

Cash consideration for 37.1 million outstanding shares of New

River common stock at US$64 per share (net of 1.5 million of

common stock repur
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 ... market research report is available in its ... Market 2014-2018 http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... Biodegradable materials are materials that are readily ... packaging differs from conventional non-degradable packaging in ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The Global ... in-depth study on the current state of the Trifluoroacetic ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
(Date:8/27/2014)... 27, 2014  Lisa Kulik saw fireworks for the ... holiday, thanks to a groundbreaking retinal implant co-invented by ... clinician-researcher at the University of Southern California (USC) Eye ... Peoria, Ariz. resident who has retinitis pigmentosa, ... sight. On June 2, she became the first person ...
(Date:8/27/2014)... 2014 Guggenheim Securities, the investment banking and ... hiring of veteran equity analyst Charles "Tony" Butler as ... will focus on the biotech/biopharma sector. " ... experience and a broad network of relationships in his ... and Head of Equities at Guggenheim Securities. "His insights ...
Breaking Biology Technology:Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2
... Patients Achieved an Objective Tumor Response by End of ... Inc. (Nasdaq: PPHM ) today reported that ... endpoint in the first stage of its ongoing Phase ... cancer (NSCLC). The open-label, Simon two-stage study is ...
... Bulletin Board: GOVX), an Atlanta-based, publicly traded,biopharmaceutical company developing ... and other infectious agents, today,announced that its Corporate Presentation ... webcast live by Thomson Reuters. The Conference will be ... February 9 and 10, 2009. , ...
... Wis., Feb. 4 Mach One Corporation (Pink Sheets: ... develops biotechnology based solutions that produce positive, long term ... that it has signed a definitive agreement to acquire ... company that supplies ingredients to the food, feed and ...
Cached Biology Technology:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 2Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 3Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 4GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference 2GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference 3Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc. 2
(Date:8/28/2014)... conserve biodiversity and more action is needed to ensure ... say. , Published in PLOS ONE , researchers ... Exeter, used meta-analysis - combining results from different studies ... research into these areas, to determine whether they actually ... Biological Sciences, said protecting an area from human exploitation ...
(Date:8/27/2014)... Wis. The mechanical force that a single fungal cell ... vanishingly small, but it plays a heavy role in setting ... In fact, it may not be too much of a ... land without the ability to respond to the touch of ... An, a professor of agronomy at the University of Wisconsin-Madison. ...
(Date:8/27/2014)... in understanding the mysteries of the human genome was ... provide the most detailed comparison yet of how the ... , The research, appearing August 28 in in ... encoded in the three species, genomes is "read out," ... chromosomes. , The results add billions of entries to ...
Breaking Biology News(10 mins):Protected areas proven to protect biodiversity 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4
... (May 24, 2010) The timing of umbilical cord clamping ... suggest researchers at the University of South Florida,s Center of ... umbilical cord for a slightly longer period of time allows ... infant and, with that critical period extended, many good physiological ...
... , WALL, N.J. , May 24 BIO-key ... identification solutions, today announced that Evidian has integrated BIO-key,s biometric software ... deployed this biometric identification solution at two major pharmaceutical companies. , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ...
... Israel Current research suggests that T helper-type ... actual inhibit the development of experimental immune encephalomyelitis (EAE), ... Th17 cells. The related report by Wildbaum et ... high CD4 + T cells restrain ...
Cached Biology News:Do we clamp the umbilical cord too soon? 2Do we clamp the umbilical cord too soon? 3BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 2BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 3BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 4When helper cells aren't helpful 2
...
cysteine and glycine-rich protein 2,...
... Antitumour agent and DNA-topoisomersae II inhibitor (IC50 = ... C 29 H 32 O 13 ... Store at: RT ... Solubility: Soluble to 100 ...
HSPBP1 Antibody...
Biology Products: